Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
What We Do
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
About Vantage
Editorial team
Products & Services
Consensus Forecasts
Pharma
EvaluatePharma
EvaluatePharma Vision
Custom Solutions
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Client Success
Customer Testimonials
Thought Leadership
English
日本語
About Us
Media Centre
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Summit Therapeutics
June 27, 2018
Summit finds that Duchenne magic is not universal
February 09, 2018
Sarepta contains UK study halt, for now
January 26, 2018
DMD-day for investors
January 12, 2018
Upcoming events – Data dates for Summit and Cytokinetics
September 06, 2017
Sarepta hopes to pull off the same trick twice
March 16, 2017
Marathon’s hot potato is now PTC’s problem
March 16, 2017
Marathon’s hot potato is now PTC’s problem
October 14, 2016
Snippet roundup: Biomarin boosted, Synairgen stung
October 06, 2016
Vantage point – What Brexit means for life science funding and strategy
October 06, 2016
Therapy focus – Duchenne assets soar in the wake of Exondys 51 approval
October 05, 2016
Sarepta pivots to business development
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
December 17, 2019
Vantage 2020 Preview
July 31, 2019
Vantage Pharma, Biotech & Medtech Half-Year Review 2019
Editor's Picks
January 09, 2020
What makes a great year for takeovers?
January 07, 2020
Surprise! There’s a tumour in which Keytruda doesn’t work
December 19, 2019
Gene therapy clinical holds take centre stage
December 20, 2019
Plenty of choice remains for buyers of gene therapy
October 14, 2019
Uncovering biopharma’s hidden treasures
